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Summary
For therapeutic studies, predictive validity of animal models – arguably the most
important feature of animal models in terms of human relevance – can be calcu-
lated retrospectively by obtaining data on treatment efficacy from human and
animal trials. Using rosiglitazone as a case study, we aim to determine the
predictive validity of animal models of diabetes, by analysing which models
perform most similarly to humans during rosiglitazone treatment in terms of
changes in standard diabetes diagnosis parameters (glycosylated haemoglobin
[HbA1c] and fasting glucose levels). A further objective of this paper was to
explore the impact of four covariates on the predictive capacity: (i) diabetes
induction method; (ii) drug administration route; (iii) sex of animals and (iv) diet
during the experiments. Despite the variable consistency of animal species-based
models with the human reference for glucose and HbA1c treatment effects, our
results show that glucose and HbA1c treatment effects in rats agreed better with
the expected values based on human data than in other species. Induction method
was also found to be a substantial factor affecting animal model performance. The
study concluded that regular reassessment of animal models can help to identify
human relevance of each model and adapt research design for actual research
goals.
Keywords: Animal models, human relevance, predictive validity, type 2 diabetes.
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Introduction
Although animal research is considered to be a central
element of contemporary biomedical science and arguably
has contributed greatly to the understanding of disease
mechanisms and development of treatments, the predictive
validity of different animal models is generally assumed
and rarely measured. Having information on this feature of
animals is crucial especially for therapeutic studies. The
predictive validity of animal models, which means ‘to what
extent research data from animals can predict human
response to particular drugs’ can be calculated retrospec-
tively, after obtaining data on treatment efficacy from
humans and animals.
Even though only human–animal comparative studies
can produce evidence on human relevance of animal
models and justify their use from a scientific point of view,
relatively few studies have addressed their methodology.
Several animal studies speculate on the translatability of
results from animal studies by assuming on the validity of
animal models. However, unique characteristics of animal
models deserve special consideration on whether results
can be translated to humans or not (1). As Garth Whiteside
has noted, comparison of large datasets from preclinical
efficacy studies and human trials is a complex matter, and
the predictive capacity of these models cannot be described
as ‘worked’, ‘didn’t work’, or ‘failed’; deeper analysis is
needed (2).
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To evaluate the predictive validity of animal models, one
may opt for (i) assessing the predictive validity of a single or
very few models by comparing treatment effects of series of
interventions (e.g. administration of anti-diabetic drugs) in
that/those animal model(s) and humans or (ii) assessing the
predictive validity of several animal models by comparing
the treatment effect of a particular intervention in those
animals and humans. In either case, this comparison should
be based on quantitative data that allow correlations
between humans and different animal species to be calcu-
lated. This requires access to data where the same quanti-
tative information (outcomes) is available for treatment
effects both in animal and human subjects. Although
research outcomes of an identical nature are regularly
reported in human and animal studies, any study selection
effort entails the setting of minimum criteria for study
design quality. Furthermore, data availability is also an
issue.
The quality of the data has a huge impact on the con-
clusions that can be drawn, but raw data are rarely pre-
sented. The ideal human data for the calculation would be
complete data from clinical trials. Because of the recent
tight regulations on clinical trials (e.g. requirement of
authorization (3) and prior registration (4)), transparency
on the conduct and results of clinical trials has been
improved. However, there are still problems with study
design and publication from these trials. Regarding design,
a widely discussed issue, among others, is the obscure man-
agement of missing data (5). Additionally, we know that
not all studies get published in their entirety after the clini-
cal trials (6); what is more, what does get published may be
different from in-house interpretation and more likely to
make a drug look favourable (7).
Also for animal data, it is increasingly evident that short-
comings in research design and publication bias resulting
from selective publishing of desirable results are the cause
of overestimated treatment effects (8,9). The retrospective
evaluation of the predictive validity of animal models
is further complicated by statistical weaknesses. Animal
studies regularly report data from small samples of
animals, and usually such studies are not repeated by inde-
pendent third-party laboratories.
An additional challenge is that of comparing different
species (10). The efficient drug dose widely varies across
species, mostly because of the pharmacokinetics of a par-
ticular drug being different from species to species (11). It
is commonly observed that small animals need to be admin-
istered larger doses (per kilogram body weight) as com-
pared with big animals or humans to achieve similar
pharmacological effects. For instance, about fivefold higher
doses of prednisolone and caffeine have been reported for
rats as compared with humans (12). Providing cross-species
comparisons of activity and toxicity of various drugs, two
important methods are used for dosage conversions. One is
based on per body surface area calculation (mg/m2), which
is the method required by the Food and Drug Administra-
tion (FDA); the alternative method considers the daily
expenditure of energy expressed per metabolically active
mass (12).
In the present paper, we propose a method for assessing
the predictive validity of several animal models. Using
rosiglitazone, a widely used pharmaceutical to treat type 2
diabetes mellitus (T2DM), we aimed to provide data on the
predictive validity of different animal models of diabetes.
Type 2 diabetes was chosen as animal models are widely
used in research into this disease (13), but their predictive
validity has never been statistically studied. Rosiglitazone is
an ideal case study to test the predictive validity of diabetes
animal models: it is widely used in human patients and a
preliminary PubMed search showed it to be the most com-
monly used pharmaceutical in animal studies into type 2
diabetes.
The main objective of this paper was to determine the
predictive validity of animal models of diabetes, by analys-
ing which models perform most similarly to humans during
rosiglitazone treatment in terms of changes in standard
diabetes diagnosis parameters (glycosylated haemoglobin
[HbA1c] and fasting glucose [FG] levels). A further objec-
tive of this paper was to explore the impact of four
covariates on the predictive capacity of animal models.
These covariates are methodological issues that often differ
across studies, namely (i) diabetes induction method; (ii)
drug administration route; (iii) sex of animals and (iv) diet
during the experiments.
Materials and methods
Literature review
Both human and animal studies were searched between
September and December 2012. Studies reporting
rosiglitazone monotherapies with information on glucose
and/or HbA1c, published in English, were included. All
references were downloaded and managed in Endnote.
Two authors (O. E. V., N. Z.) assessed studies and
extracted data into an excel table (Microsoft Office Excel
2007). Data on study design elements including time, route
and dose of the drug administration, the species and strain
of the animal, age and sex/gender of subjects, diets, diabe-
tes induction method, outcomes (i.e. FG and HbA1c levels
– number of observations, mean, variability measure) in
each study group were extracted. In those papers where
data were only reported graphically, a digital online ruler
(14) was used to gain numerical values.
Animal studies were identified from Pubmed and Web of
Science using the following algorithms. Pubmed search:
(‘animal experimentation’[MeSH Terms] OR ‘models,
animal’ [MeSH Terms]) AND ‘rosiglitazone’ [Supplemen-
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tary Concept] AND ‘blood glucose’ [MeSH Terms]. Web
of Science: Topic = (rosiglitazone) AND Topic = (blood
glucose) AND Topic = (animal) AND Topic = (search filter
suggested by Carlijn R Hooijmans (15)). The selection
method with exclusion criteria is presented in Fig. 1a. A
total of 71 studies were included.
Human studies were identified from three sources. A
PubMed search that used the algorithm: ‘Blood Glucose’
[Mesh] AND ‘Hemoglobin A, Glycosylated’ [Mesh] AND
‘Diabetes Mellitus, Type 2/drug therapy’ [Mesh] AND
‘rosiglitazone’ [Supplementary Concept] AND ‘Thiazoli-
dinediones/therapeutic use’[Mesh] AND ‘Randomized
Controlled Trial’ [ptyp] AND English [lang]. In addition,
one study (16) from a published metaanalysis on the effi-
cacy of thiazolidinediones (the class of drugs that include
rosiglitiazone) in the Asian population (17) was included.
Finally, all monotherapy studies were identified and
included in the analysis from the website of the pharma-
ceutical company GlaxoSmithKline (GSK) who made all
studies on rosiglitazone available through the company’s
website (18). Details along with exclusion criteria are
shown in Fig. 1b.
Parameters and factors analysed
To evaluate the predictive capacity of different animal
models, human and animal HbA1c and FG levels were
selected as outcome measures. HbA1c is the primary
laboratory test for diabetes in human studies and reflects
average blood glucose for the preceding 60–90 d, whereas
FG level is a very common parameter to monitor diabetes.
To evaluate the effect of certain factors that often differ
across studies and may cause methodological issues, the
following were considered: (i) diabetes induction method;
(ii) drug administration route; (iii) sex of animals and (iv)
diet during experiments. Rationale of selecting these
covariates is given later.
1. A number of diabetic animal models have been devel-
oped over the years, based mostly on rodents; these models
can be classified into two broad categories: (i) genetically
induced spontaneous diabetes models and (ii) experimen-
tally induced (non-spontaneous) diabetes models (19). The
second consists of several subtypes: streptozotocin (STZ)/
alloxan models, partial pancreatectomy models, high-fat
(HF)/high-sucrose diet-fed models, HF diet-fed STZ
models, and intrauterine growth retardation models (19).
2. Several drug administration methods have been used
to introduce the chemical substance. Oral administration,
subcutaneous administration and intraperitoneal injection
of substances are common procedures in scientific experi-
ments (20).
3. As diet has a significant impact on diabetes’s induc-
tion and progress, diet is a crucial part of the experimen-
tation, whether spontaneous or experimentally induced
models are used (21).
Figure 1 Procedure on selection of studies. (a) Procedure chart on how animal studies were selected. (b) Procedure chart on how human studies
were selected.
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4. The sex of animals has a well-documented impact on
diabetes mellitus progress, which may imply gender-specific
clinical treatment of diabetes (22).
Statistical modelling and analysis
Information from all included studies was extracted and
entered into a single database with as many observations
for each study as the number of FG and/or HbA1c outcome
measurements reported at distinct follow-up times in that
study. Outcome level means and their standard errors were
logarithmically transformed (natural base) using appropri-
ate formulas to derive the expected value and standard
error of the transformed variable working from the mean
and standard error of the source variable. Treatment effect
estimates at each observation time were calculated as the
between-groups (rosiglitazone versus placebo) difference in
transformed outcome levels. Treatment effect standard
errors were calculated as the square root of the sum of
group-specific squared standard errors. For the analysis of
species effect, only rats and mice were included, whereas
the remaining analyses were done on the complete dataset,
including the two single studies on hamster and gerbil. For
this reason animal strains in Fig. 2a,b, are referred to as
‘Rat’ and ‘Mouse’.
Linear regression models were fitted on human observa-
tions for both outcomes. The dependent variable was the
treatment effect; explanatory variables included dose, time
into exposure (natural logarithm of week) complete with a
quadratic derivative, and interaction terms between dose
and time. Observations were weighted proportionally to
their precision (reciprocal of squared standard error of
treatment effect). The distribution of dose values was
bimodal; a low- vs. high-dose categorization cut-off of
6.5 mg was observed to coincide with a fairly wide gap
between the two modes, close to the sample 50th percen-
tile. To verify that this categorization did not cause sub-
stantial loss to model fit and/or changes to results and
conclusions, the analysis was also completed using dose as
a continuous variable, transforming rat doses (mg intake)
to a human-comparable scale dividing by 2.25, and non-rat
murine doses by dividing by 11.25, in accordance with
FDA guidelines regarding interspecies dose conversion (3).
Model fit was evaluated using normality tests of residuals
and Ramsey’s regression specification-error tests, neither of
which indicated any insufficiency of fit (all P ≥ 0.195).
Coefficients derived from the human models were used
to calculate expected values of non-human treatment
effects. For each included study, and for each level of strain,
diabetes induction method, special diet (yes or no), sex and
drug administration route within the study if applicable,
differences between observed and expected treatment
effects were squared, summed, divided by the number of
Mouse
n = 244, P = 0.0023
(a)
(b)
(c)
Rat
Animal species
Mouse
n = 69, P = 0.0446
Rat
Animal species
1.5
1.0
0.5
0
1.0
0.8
0.6
0.4
0.2
0
db/db mouse BALB/c mouse Other mouse
C57BL mouse apoE deficient
mouse
Sprague Dawley
rat
ZDF rat
Mouse strains: n = 113, P = 0.0000; rat strains: n = 131, P = 0.2199
Wistar rat Other rat
strain
1.5
1.0
0.5
0
Figure 2 Comparing the animal models with the human reference for
glucose and glycosylated haemoglobin (HbA1c) treatment effects. (a)
Deviation scores for glucose treatment effects under rosiglitazone
monotherapy in mice and rats. Horizontal lines of pluses indicate
sample means; n denotes number of observations. (b) Deviation scores
for HbA1c treatment effects under rosiglitazone monotherapy in mice
and rats. Horizontal lines of pluses indicate sample means; n denotes
number of observations. (c) Deviation scores for glucose treatment
effects under rosiglitazone monotherapy in rat and mouse strains.
Horizontal lines of pluses indicate sample means. Strains rarely used in
studies are pooled as ‘other mouse’ and ‘other rat’; n denotes number
of observations.
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measurement occasions, and taken the square root of.
Values so derived were referred to as deviation scores.
The effects of factors raising methodological issues, such
as species, induction method, diet, sex and administration
route were evaluated by comparing groups in terms of
deviation scores. Basic unadjusted comparisons were made
using simple linear regression. Adjusted effect estimates
were obtained using multiple linear regression. Deviation
scores were log-transformed to improve normality. Robust
standard errors based on the clustering of observations
within studies were used to make the estimation consistent
with the presence of non-independence among observa-
tions coming from the same study. Explanatory variables
with negligible effect estimates on both outcomes and no
appreciable role as adjustment or interaction factors were
eliminated to ensure model parsimony.
All statistical calculations and analyses were done using
the software package Stata version 11. The detailed proto-
col of data collection and analysis is available as Support-
ing Information Appendix S1.
Results
General description of dataset
As a result of rosiglitazone treatment, hyperglycaemia ame-
liorated in both diabetic animals and patients with T2DM.
The dose used to efficiently reduce blood glucose and
HbA1c levels in animals varied considerably across studies
(6–20 mg/kg). Generally speaking, higher doses are used in
animals than humans. In T2DM patients, rosiglitazone
reduced fasting blood glucose and HbA1c levels at a daily
dose of 4–8 mg. Animal studies differed from studies in
human patients in terms of the age of study subjects: the
initial age of human patients corresponded to late adult-
hood whereas that of animals represented adolescence and
early adulthood. In animal studies the impact of treatment
was detected by a comparison of glucose and HbA1c levels
between treatment and placebo groups, whereas 30 out of
62 human studies presented data as compared with base-
line measurements (see Fig. 1), that could not be used for
our analysis. Table 1 shows main characteristics of study
subjects and glucose and HbA1c parameters from human
and animal studies.
Comparing the consistency of animal models with
the human reference for glucose and HbA1c
treatment effects
All analyses shown later refer to models using dose as a
categorical factor as no appreciable differences from results
obtained with the continuous formulation were observed.
Rodent models roughly agreed with human data, espe-
cially for rats, but showed considerably varied accuracy in
Table 1 Characteristics of subjects in the studies
Human Rat Mouse Gerbil Hamster
List of strains (number of
studies, number of
animals)
22, 3076 Brown Norway (1, 18) (apo)E2 knock-in mice (1, 20) Gerbil (1, 32) Syrian Golden
(1, 30)Dahl SS/JrHsd (1, 20) A-ZIP (1, 12)
Goto Kakizaki (1, 13) BALB/c (1, 40)
LETO (1, 10) C57BL6J (3, 70)
OLETF (1, 10) DBA/2J (1, 63)
Ob-ZSF1 (1, 30) FVB/N (1, 12)
Sprague Dawley (12, 293) KKAgamma (1, 12)
Wistar (9, 189) Ldlr−/−Apob100/100Lepob/ob (1, 23)
ZDF (14, 251) MKR (1, 12)
Zucker lean (2, 32) Swiss albino (2, 30)
apoE deficient (2, 96)
db/db (14, 214)
ob/ob (4, 52)
Initial age, weeks – weighted
arithmetic mean (SD)
58.50 (8.93)
years
8.59 (4.51) 7.05 (2.53) 16.00 (0.00) 9.00 (0.00)
Experimental time, weeks 27.09 (15.10) 5.47 (5.44) 8.53 (7.05) 2.00 (0.00) 5.00 (0.00)
Average dose used,
mg kg d−1
4.87 (2.00) 6.49 (6.95) 11.59 (15.48) 20.00 (0.00) 7.15 (0.00)
Glucose level after treatment,
mmol L−1
8.44 (2.21) 10.58 (2.57) 13.28 (8.72) 6.34 (3.70) 3.50 (2.32)
HbA1c after treatment, % 7.69 (1.13) 4.71 (0.73) 7.19 (2.93) No data No data
Information provided in the table is based on all study subjects either treated with rosiglitazone or receiving no treatment, except for the rows
‘Glucose level after treatment’ and ‘HbA1c after treatment’ which include only treated groups. Means and standard deviations were pooled across
studies by weighted averaging based on sample sizes, means and standard deviations reported for each study.
SD, standard deviation.
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reflecting the efficacy of rosiglitazone in humans. For
clarity, data on human-scaled values are provided in
Table 2. The table shows how glucose and HbA1c levels
differed in the rosiglitazone versus the placebo arms in
humans at various time points into follow-up. For example,
in low dose treatment at 3 weeks, the average glucose level
in the rosiglitazone arms was 85.9% of that in the placebo
arms, or, in other words, a reduction of about 14% can be
estimated as the treatment effect. For simplicity, data at
median and terminal follow-up time points were used to
illustrate the tendencies.
Analysis of the 69 publications reporting studies with
rats and mice (the single hamster and gerbil study excluded
from this analysis) showed that the consistency of animal
species-based models with the human reference for glucose
and HbA1c treatment effects is highly variable. Glucose
and HbA1c treatment effects in rats agreed better with the
expected values based on human data than in mice, indi-
cating that rat-based models may have greater consistency
than those based on other species. Figure 2a shows that rats
had significantly lower scores of deviation from the human
reference than mice for glucose treatment effects during
rosiglitazone treatment (means: 0.275 vs. 0.594, respec-
tively; P = 0.0023, unadjusted analysis). In case of HbA1c
treatment effects, rats had the lowest deviation scores again
(0.385 on average, vs. 0.639 in mice), and the unadjusted
difference was borderline significant (Fig. 2b, P = 0.0446).
Strains
The question regarding which strain is the most appropri-
ate to model the clinical efficacy of rosiglitazone could not
be conclusively answered. In the analysed studies, 10 rat
strains, 11 mouse strains and 2 other species were used.
Although Sprague Dawley rats and C57BL/6 mice seemed
to be the most consistent animal models for the clinical
efficacy of rosiglitazone, no statistical difference in devia-
tion scores was observed among groups. The strain pre-
senting the least consistent results for the clinical efficacy of
rosiglitazone (in terms of both glucose and HbA1c treat-
ment effects, with mean deviation scores 0.801 and 0.698,
respectively) was the commonly used db/db mouse. Data
on rat and mouse models are presented in Fig. 2c.
Impact of animal study covariates – induction
method, drug administration route, sex of animals
and applied diet
From the point of view of similarity to the human response
to rosiglitazone, STZ induction was observed to be the
most appropriate induction method, as presented in
Fig. 3a. STZ-induced diabetic animal models had the
highest average consistency (mean deviation score: 0.237)
with the human reference as evaluated in terms of the
treatment effects of rosiglitazone on glucose levels. Per-
forming a similar analysis for HbA1c was not practicable
because of the low number of relevant studies.
Comparing the three administration methods, oral
gavage was associated with the lowest deviance scores
(mean: 0.369 for glucose, 0.449 for HbA1c). Of note, the
number of observations for peritoneal administration was
relatively small, and the unadjusted difference was only
borderline significant for glucose (Fig. 3b) and non-
significant for HbA1c (Fig. 3c).
To test the hypothesis that humanized (high-sucrose,
HF) or other diets could have an impact on diabetes onset
and progress, and thereby on the consistency between
animal and human models, deviation scores were com-
pared across groups defined by high-sucrose, HF, high-
sucrose-HF, and low-fat diets. No link was found between
diet and the performance of animal models. Similarly, the
sex of the animals was not observed to affect the devia-
tion between animal and human models. Raw data asso-
ciated with factors representing covariates are shown in
Table 3.
In multiple regression analysis, species, induction
method and drug administration route were found to be
substantial factors of animal model performance (Table 4).
Adjusted for induction method and administration route,
rat models performed better: the difference in deviation
scores between rats and other species was strongly signifi-
cant for the FG outcome, although not quite for HbA1c.
STZ as an induction method was found to better approxi-
mate the relationship between rosiglitazone exposure and
treatment effect, observed in humans, than other methods,
especially when treatment effect was assessed through
HbA1c levels. The data also suggest that intraperitoneal
Table 2 Ratios of glucose and HbA1c levels between the rosiglitazone and placebo arms in human studies at different times into follow-up
Fasting glucose level ratios,
rosiglitazone versus placebo
HbA1c level ratios,
rosiglitazone versus placebo
Low-dose group, median follow-up 3 weeks 0.859 (0.478–1.545) 8 weeks 0.940 (0.908–0.974)
Low-dose group, end of follow-up 52 weeks 0.817 (0.691–0.965) 52 weeks 0.894 (0.811–0.985)
High-dose group, median follow-up 3 weeks 1.056 (0.976–1.143) 8 weeks 1.027 (0.998–1.057)
Low-dose group, end of follow-up 52 weeks 0.870 (0.824–0.918) 52 weeks 0.992 (0.953–1.034)
Parentheses include 95% confidence intervals.
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administration may result in poorer consistency between
human and animal models than per os administration.
Discussion
Clear understanding on the predictive validity of animal
models is in those fields of applied drug testing where
several animal models are used. In this study, we presented
a method to statistically evaluate the predictive validity of
animal model studies. Using rosiglitazone in diabetes as a
case study and comparing treatment effects between human
and animal studies, we showed that studies in rats are
better predictors of results in humans than other animal
model studies. Agreement between human and animal
studies was further affected by disease induction method
and drug administration route. This was the first time that
the concept of predictive capacity of animal models was
systematically approached in type 2 diabetes pharmaceuti-
cal studies.
Our case study of rosiglitazone had two research ques-
tions: to compare treatment effect of rosiglitazone in
human and animal models in order to identify which is
more relevant to humans, and to understand the impact of
experimental diet, induction method, sex and administra-
tion route of rosiglitazone on the treatment effect of
rosiglitazone.
According to the research question on the human rel-
evance of animal models, our findings showed that
although the consistency of animal species-based models
with the human reference for glucose and HbA1c treatment
effects are highly variable, glucose and HbA1c treatment
effects in rats agreed better with the expected values based
on human data than in other species; rats had significantly
lower scores of deviation from the human reference than
mice for glucose and HbA1c treatment effects. The ques-
tion regarding which strain is the most appropriate to
model the clinical efficacy of rosiglitazone could only be
tentatively answered. There was no statistical difference in
deviation scores observed between rat groups; among
mouse strains, C57BL/6 showed the most consistent, while
db/db showed the least consistent results.
Since models differ in physiological and genetic rel-
evance, there is no single diabetic animal model which
would fit for all scientific purposes; ideally, more than one
species or strain are used in each study (13). Three different
approaches are used to evaluate the reliability of animal
models: the first is phenomenological/pathophysiological
similarity of the model to the syndrome it is imitating (face
validity), the second compares the etiology of diseases in
animal models and humans (construct validity), and the
third approach refers to the ability of the model to respond
to appropriate medications (predictive validity) (23). The
vast majority of reviews on T2DM animal models gives
information on the models’ face and construct validity,
STZ only
n = 244, P = 0.0392
(a)
(b)
(c)
OtherSP only
Intervention type
1.5
1.0
0.5
0
per os
n = 241, P = 0.0442
IntraperitonealOral gavage
Drug administration
1.5
1.0
0.5
0
per os
n = 69, P = 0.0907
Oral gavage
Drug administration
1.0
0.8
0.6
0.4
0.2
0
Figure 3 Impact of animal study covariates. (a) Deviation scores for
glucose treatment effects under rosiglitazone monotherapy in groups
by diabetes induction method. ‘STZ only’ denotes the use of
streptozotocin (STZ) only; ‘SP only’, the absence of exogenous
(non-spontaneous) induction methods; ‘other’ denotes models that were
not used frequently enough for individual analysis (alloxan models,
partial pancreatectomy models, high-fat/high-sucrose diet-fed models,
high-fat diet-fed STZ models, and intrauterine growth retardation
models). Horizontal lines of pluses indicate sample means; n denotes
number of observations. (b) Deviation scores for glucose treatment
effects under rosiglitazone monotherapy in groups by drug
administration route. Horizontal lines of pluses indicate sample means;
n denotes number of observations. (c): Deviation scores for HbA1c
treatment effects under rosiglitazone monotherapy in groups by drug
administration route. Horizontal lines of pluses indicate sample means;
n denotes number of observations.
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categorized by species. The characteristics of often used
species such as murine models (24), monkeys (25) canines
(26) or pigs (27) are widely discussed. As it was noted, very
few studies on T2DM addressed the translatability of
animal research results to humans and how to select animal
models with ‘higher human relevance’. A recent study has
pointed out that genetic similarities between humans and
certain species can be useful for appropriate model selec-
Table 3 Description of factors that may
cause methodological issues (covariates) in
animal studies
Rat Mouse Gerbil Hamster
Induction method (number of studies,
number of animals)
SP 27, 350 21, 208 1, 16 1, 15
SP + STZ 1, 8
SP/diet 1, 10
GM 6, 58
GM + STZ 2, 24
Alloxan 1, 5 5, 101
Dexamethasone 1, 6 1, 7
Diet 2, 14
Low protein IU diet 1, 7
Streptozotocin 13, 135
Surgery 1, 20
Administration route (number of studies,
number of animals
Per os 14, 139; 1, 10 12, 129
Oral gavage 24, 394 15, 250 1, 16 1, 15
Intraperitoneal injection 1, 12 2, 13
Unknown 1, 10 1, 6
Diets (number of studies, number of animals
High-NaCl 1, 10
High-energy 1, 16
High-fat 7, 77 6, 103 1, 15
High-fat-high-sucrose 1, 8
Low-fat 1, 5
Normal diet 24, 265 21, 275
Unknown diet 8, 195 2, 15
Sex in animals in absolute numbers
Male 401 318 16 15
Female 36 18 0 0
Both or unknown 118 62 0 0
GM, genetically induced models; SP, spontaneous diabetes models; STZ, streptozotocin models; IU,
intrauterine.
Table 4 Additive effects of animal study
factors on deviation scores of animal models
Factor Contrast Effect 95% CI P
Outcome: fasting glucose
Species Rat versus mouse −0.790 −1.255 −0.325 0.001
Intervention SP only versus STZ only 0.505 −0.086 1.097 0.093
Intervention Other versus STZ only 0.151 −0.722 1.023 0.731
Administration route Oral gavage versus per os −0.188 −0.666 0.290 0.434
Administration route Intraperitoneal versus per os 0.650 0.130 1.169 0.015
Outcome: HbA1c
Species Rat versus mouse −1.577 −3.257 0.103 0.063
Intervention SP only versus STZ only 3.179 1.020 5.339 0.008
Intervention Other versus STZ only 4.937 2.494 7.379 0.001
Administration route Oral gavage versus per os −0.867 −2.131 0.397 0.159
Additive effects of animal study factors on deviation scores of animal models with respect to the
human reference for the relationship between rosiglitazone exposure and treatment effect on
follow-up levels of fasting glucose and HbA1c.
CI, confidence interval.
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tion (28) and another study categorized mouse models by
outcome measures that are used in the clinical practice of
diabetic nephropathy (29).
A generally good correlation between human and animal
experimental outcomes is often assumed in pharmacologi-
cal studies, not considering the impact of the species effect.
For example, the use of the leptin-deficient mouse (ob/ob)
in type 2 diabetes research is widely recommended in any
pharmaceutical research (30), but our case study does
not prove ‘high predictive validity of this model’ for
rosiglitazone efficacy in humans. This example points out
that if we want to understand how reliable our animal
models are in a particular situation, results must be (re)as-
sessed in the light of human data.
Concerning our second research question, in multiple
regression analysis, induction method, and drug adminis-
tration route were studied, and the induction method was
found to be a substantial factor affecting animal model
performance. STZ as an induction method was associated
with better approximation of the human relationship
between rosiglitazone exposure and treatment effect than
other methods, especially when treatment effect was ascer-
tained through HbA1c levels. Although this result gives
significant input for experimental design, it has to be under-
lined that these specific comparisons were complicated
because HbA1c level, which is the primary outcome of
human studies, was less frequently reported in animal
studies (30).
There are several established methods for determining
glycated haemoglobins (31) and many of them are used in
rodents (32). The relation between HbA1C and plasma
glucose levels in diabetes animal models has also been well
described (33). However, in an ideal case, free plasma con-
centration of rosiglitazone could be compared between
human and animal subjects, and identify how much of the
drug is in the blood.
One of the strengths of this study is that to ensure suf-
ficient coverage of relevant literature, it goes beyond tradi-
tional information sources; data from unpublished human
studies have also been involved in the analysis. A very
complex and long lawsuit filed against GSK started in
2007. One of the consequences of the legal action against
GSK was that all studies performed by the company were
made available through the company’s website (18) and
thus became available for our analysis. On the other hand,
there are specific limitations to this work, such as the
presence of different characteristics in human versus animal
studies, which impeded the immediate comparability of the
two datasets. One of these constrains was that the dose
used to efficiently reduce blood glucose and HbA1c levels
in animals varied considerably between studies (6–20 mg/
kg). Generally speaking, higher doses are used in animals
than humans. Additionally, in animal studies, the impact of
treatment was detected by a comparison of glucose and
HbA1c levels between treatment and placebo groups; con-
sequently, single-arm human studies that presented data as
compared with baseline measurements, i.e. without a
placebo control, could not be used in the analysis. Another
problem was that the age of the study populations differed:
the initial ages of human patients correspond to late adult-
hood whereas that of animals represents adolescence and
early adulthood.
Animal models are unique in their predictive value for
human drug efficacy. This study aimed to present how the
predictive validity of animal models can be assessed retro-
spectively. Our method shows that regular reassessment of
animal models helps to identify ‘human relevance of each
model’ and adapt research design for actual research goals.
Although our findings are important, one should be careful
with interpretation of results presented here; extrapolation
of our results outside the thiazolidinedione class of drugs
should be avoided.
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